Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10617099 | 0.83 | L3MBTL1 (0.54) | MMP2MMP3L3MBTL1 | |
| SCHEMBL6742053 | 0.83 | KDM4E (0.60) | MMP2MMP3 | |
| SCHEMBL9707353 | 0.81 | LSS (0.62) | MMP2MMP3 | |
| SCHEMBL12418966 | 0.79 | PPARA (0.45) | MMP2FDPSL3MBTL1MAOAMAOB | |
| SCHEMBL10619007 | 0.79 | KCNA3 (0.53) | MMP2MMP3FDPSL3MBTL1 | |
| SCHEMBL12534316 | 0.76 | KMT2A (0.56) | CYP1A2CYP3A4CYP2C19BLMPMP22 | |
| SCHEMBL3444779 | 0.75 | KDM4E (0.69) | CYP1A2CYP3A4CYP2C19BLMPMP22 | |
| SCHEMBL9783690 | 0.75 | NR4A2 (0.51) | L3MBTL1 | |
| SCHEMBL10617883 | 0.75 | MMP2 (0.61) | MMP2MMP3L3MBTL1 | |
| SCHEMBL9707448 | 0.73 | MMP2 (0.72) | MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693217-B2 | BACTERICIDES AGAINST PLASMODIUM OR MYCOBACTERIUM SPECIES | JACOBUS PHARMACEUTICAL CO., INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030144361-A1 | Antimalarial N,N'-subistituted biguanides derived from hydroxylamines | JACOBUS PHARMACEUTICAL CO., INC. | 2003-07-31 | — | — | US | disclosed |
| US-6551614-B2 | Protecting from malaria without causing testicular atrophy by administering 1-(3-(3,4-dichlorophenoxy)propyloxy)-5-isopropylbiguanide(hemisuccinate) | JACOBUS PHARMACEUTICAL CO., INC. | 2003-04-22 | — | — | US | disclosed |
| US-20030040544-A1 | Antimalarial N,N'-substituted biguanides derived from hydroxylamines | JACOBUS PHARMACEUTICAL CO. INC. | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040544-A1 | Antimalarial N,N'-substituted biguanides derived from hydroxylamines | G6PD, HBG1, FPGS | MMP2 2305/4885MMP3 3602/4885CYP1A2 588/4885 |
| US-20030144361-A1 | Antimalarial N,N'-subistituted biguanides derived from hydroxylamines | G6PD, HBG1, BHMT | MMP2 2178/4885MMP3 3285/4885CYP1A2 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.